Medtronic completes MiniMed Group separation
Medtronic plc completed the separation of MiniMed Group, Inc. on October 15, 2026, through an exchange offer, disposing of its entire stake in the company.

MDT Health Care · 3 analyses
Medtronic reported $9.8B in revenue (+13.7% YoY), compared with a +7.2% median across covered Health Care peers. 3 insider sales recorded.
Medtronic plc completed the separation of MiniMed Group, Inc. on October 15, 2026, through an exchange offer, disposing of its entire stake in the company.
Medtronic has completed an exchange of shares for its interest in MiniMed Group, accepting 55,032,401 of its own shares. This action completes the company's divestiture of all remaining interest in MiniMed.
Medtronic plc commenced an exchange offer on September 14, 2026, under which up to 225,361,295 newly issued MiniMed shares may be exchanged for Medtronic common shares. On October 7, 2026 the company announced the final ratio — 4.5939 MiniMed shares for each Medtronic share, which determines the size of the future issuance and the potential reduction of Medtronic shares.
Medtronic plc: 12 recorded developments from 2 official sources in 2026-10.
Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.
From the 10-Q for the period ended July 31, 2026, filed September 3, 2026. SEC
| Latest | Earlier | Change | |
|---|---|---|---|
| Revenue quarter | $9.8B | $8.6B | +13.7% |
| Operating income quarter | $1.8B | $1.4B | +22.1% |
| Net income quarter | $1.5B | $1B | +41.3% |
| Diluted EPS quarter | $1.14 | $0.81 | +40.7% |
| Operating cash flow quarter | $1.8B | $1.1B | +64.8% |
| Cash and cash equivalents balance | $1.7B | $1.9B | -13.2% |
As the company tagged them in its filing (SEC XBRL). Quarter and year figures are compared with the same period a year earlier, balances with the previous balance sheet. Download CSV
How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.
| Company | Latest revenue | Revenue YoY | Operating margin |
|---|---|---|---|
| Medtronic plc MDT | $9.8B | +13.7% | 18.1% |
| Unitedhealth Group Inc UNH | $113B | -0.4% | 5.8% |
| Mckesson Corp MCK | $111B | +7.6% | 1.4% |
| CVS Health Corp CVS | $108B | +5.4% | 3.3% |
| Cigna Group CI | $73.7B | +5.6% | 3.3% |
| Cardinal Health Inc CAH | $67.5B | +5.5% | 1.1% |
| Elevance Health, Inc. ELV | $51.4B | +1.4% | 2.5% |
Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.
Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.
| Date | Event | Filing |
|---|---|---|
| October 19, 2026 | Director or officer departure or appointment (8-K item 5.02) | 8-K |
As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.
| Date | Person | Trade | Shares | Avg. price | Value | Filing |
|---|---|---|---|---|---|---|
| October 15, 2026 | Geoffrey Martha | Sale 10b5-1 plan notice filed | 50,000 | $95.00 | $4,750,000 | SEC |
| October 15, 2026 | Michael Marinaro | Sale 10b5-1 plan notice filed | 10,420 | $96.00 | $1,000,320 | SEC |
| September 16, 2026 | Harry Skip Kiil | Sale notice filed | 1,483 | $93.65 | $138,883 | SEC |
| Fund | Shares | Value | Change in shares | Quarter |
|---|---|---|---|---|
| BlackRock | 118,770,885 | $10,248,739,689 | +4.2% | Q3 2026 |
| State Street | 65,987,354 | $5,741,305,775 | +4.1% | Q3 2026 |
| Geode Capital Management | 30,879,777 | $2,654,207,843 | +2.3% | Q3 2026 |
| Norges Bank (Norway's sovereign fund) | 16,551,016 | $1,294,785,982 | — | Q2 2026 |
| Capital Research Global Investors | 12,109,295 | $1,044,914,582 | -8.7% | Q3 2026 |
| Millennium Management | 7,772,366 | $670,677,462 | +746.2% | Q3 2026 |
| Wellington Management | 6,548,154 | $565,040,209 | +1.1% | Q3 2026 |
| Citadel Advisors | 3,773,088 | $325,579,764 | -29.8% | Q3 2026 |
| Fidelity (FMR) | 3,009,048 | $259,650,702 | -9.2% | Q3 2026 |
| Two Sigma Investments | 2,117,561 | $182,724,339 | -34.7% | Q3 2026 |
| Renaissance Technologies | 887,841 | $76,611,800 | -72.0% | Q3 2026 |
| D. E. Shaw & Co. | 795,277 | $68,624,452 | -81.9% | Q3 2026 |
| Bridgewater Associates | 488,043 | $42,113,230 | +1.1% | Q3 2026 |
| T. Rowe Price | 9,209,495 | $794,688 | +21.6% | Q3 2026 |
From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.